Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
December 19, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
December 18, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
November 19, 2024 08:00 ET
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024 16:25 ET
|
Oruka Therapeutics, Inc.
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro...
Oruka Therapeutics to Present at Multiple November Investor Conferences
November 04, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
September 25, 2024 07:08 ET
|
Oruka Therapeutics, Inc.
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding...
Oruka Therapeutics Announces $200 Million Private Placement
September 12, 2024 07:05 ET
|
Oruka Therapeutics, Inc.
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new...
Oruka Therapeutics Announces Accelerated Clinical Timelines and Upcoming Presentation at EADV Supporting ORKA-001’s Profile as a Potentially Best-in-Class Half-Life Extended Antibody Targeting IL-23p19
September 12, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody (mAb), first-in-human dosing now expected first quarter 2025 ORKA-002, a novel half-life extended IL-17A/F mAb, first-in-human...
Oruka Therapeutics Announces Closing of Merger with ARCA biopharma and Previously Announced Private Placement of $275 Million
September 03, 2024 07:00 ET
|
Oruka Therapeutics, Inc.
Oruka is advancing a pipeline of potentially best-in-class biologics that aim to offer greater freedom from disease to people with plaque psoriasis and other associated conditions Company on track to...
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
June 26, 2024 08:00 ET
|
Oruka Therapeutics, Inc.
Paul Quinlan joins as General Counsel Alan Lada joins as VP of Investor Relations Kristine Ball, President & CEO of Antiva Biosciences, appointed to Board of Directors MENLO...